Ketoconazole
This medicinal product should always be used in accordance with the description in the patient information leaflet or as directed by a doctor or pharmacist.
Nizoral, in the form of a medicinal shampoo, is an antifungal medicinal product for topical use on the skin. The medicinal product contains the active substance ketoconazole.
Nizoral, medicinal shampoo, is indicated for the treatment and prevention of the following skin diseases caused by yeast of the genus Malassezia(previously called Pityrosporum):
Before starting to use Nizoral, medicinal shampoo, a doctor or pharmacist should be consulted.
It is necessary to consult a doctor, even if the following warnings concern situations that have occurred in the past.
In the case of previous long-term topical corticosteroid treatment, in order to avoid exacerbation of disease symptoms after discontinuation of their use, the doctor will recommend gradual (over 2 to 3 weeks) withdrawal from corticosteroid treatment. The skin may react with redness and itching if corticosteroids are discontinued too quickly.
Any doubts should be clarified with a doctor.
Contact of the medicinal product with the eyes should be avoided. If this happens, the eyes should be rinsed with water.
Seborrhoeic dermatitis and dandruff are often accompanied by increased hair loss, which can also occur, although rarely, during the use of Nizoral, medicinal shampoo.
No data available.
The doctor or pharmacist should be informed about all medicinal products currently being taken or recently taken by the patient, as well as about medicinal products that the patient plans to take.
If the patient is pregnant or breastfeeding, thinks she may be pregnant, or plans to have a child, she should consult a doctor or pharmacist before using this medicinal product.
Nizoral, medicinal shampoo, may be used during pregnancy and breastfeeding if, in the doctor's opinion, it is absolutely necessary.
The medicinal product contains 0.8 μg of benzyl alcohol in each gram of shampoo. Benzyl alcohol may cause mild local irritation and allergic reactions.
The medicinal product contains 1.2 μg of benzoic acid in each gram of shampoo. Benzoic acid may cause local irritation.
The medicinal product may cause local skin reactions (e.g., contact dermatitis) or eye and mucous membrane irritation.
This medicinal product should always be used exactly as described in this patient information leaflet or as directed by a doctor or pharmacist. In case of doubt, a doctor or pharmacist should be consulted.
The medicinal product is intended for topical use on the skin in adolescents (over 12 years of age) and adults.
Unless otherwise directed by a doctor, Nizoral, medicinal shampoo, is usually used as described below.
Treatment:
Pityriasis versicolor: use once a day for one day.
Seborrhoeic dermatitis and dandruff of the scalp: use twice a week for 2 to 4 weeks.
Prevention:
Seborrhoeic dermatitis and dandruff of the scalp: use once a week or once every two weeks.
In case of any further doubts about the use of this medicinal product, a doctor or pharmacist should be consulted.
The medicinal product should not be used in children under 12 years of age.
The safety and efficacy of Nizoral, medicinal shampoo, in infants and children under 12 years of age have not been established.
Topical use of Nizoral, medicinal shampoo, in accordance with the indications and method of administration, does not pose a risk of overdose.
In case of accidental ingestion of the medicinal product, a doctor should be contacted immediately.
To avoid aspiration of gastric contents, gastric lavage should not be performed, nor should vomiting be induced.
Like all medicinal products, this medicinal product can cause side effects, although not everybody gets them.
During treatment with Nizoral, medicinal shampoo, the following side effects may occur:
Uncommon (in more than 1 in 1000 and less than 1 in 100 patients): at the site of application, redness, irritation, hypersensitivity, itching, reaction, and pustules may occur. Uncommonly, eye irritation and increased tearing, as well as hypersensitivity, folliculitis, acne, hair loss, contact dermatitis, dryness of the skin, abnormal hair structure, rash, burning sensation, and skin disorders, exfoliation of the skin, and taste disturbances may occur.
Very rare (in less than 1 in 10,000 patients): after the marketing of Nizoral, medicinal shampoo, urticaria, angioedema, and changes in hair color have been reported.
If any side effects occur, including any side effects not listed in the leaflet, the doctor, pharmacist, or nurse should be informed. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
tel.: +48 (22) 49 21 301
fax: +48 (22) 49 21 309
website: https://smz.ezdrowie.gov.pl
Reporting side effects will allow for the collection of more information on the safety of the medicinal product.
Keep out of sight and reach of children.
Do not store above 25°C.
Do not use this medicinal product after the expiry date stated on the packaging.
The expiry date refers to the last day of the month stated.
Medicinal products should not be disposed of via wastewater or household waste. A pharmacist should be asked how to dispose of medicinal products that are no longer used. This will help protect the environment.
Packaging
A 120 ml bottle of medicinal shampoo in an HDPE bottle, placed in a cardboard box.
For more detailed information, the marketing authorization holder or parallel importer should be contacted.
Clonmel Healthcare Ltd.
Clonmel, Co. Tipperary, Ireland
Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse, Belgium
McGregor Cory Ltd
Middleton Close, Banbury, Oxon OX16 4RS, United Kingdom
Clonmel Healthcare Ltd.
Clonmel, Co. Tipperary, Ireland
STADA Arzneimittel AG
Stadastrasse 2-18, Bad Vilbel, Germany
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Ireland, the country of export, authorization number: PA 126/315/002
Date of approval of the leaflet:23.08.2023
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.